ESMO Asia 2023 | First-line treatments in metastatic prostate cancer

Deborah Mukherji, MBBS,FRCP, Clemenceau Medical Center, Dubai, UAE, discusses different first-line treatment options for patients with metastatic hormone-sensitive prostate cancer. Many Asian patients present with metastatic disease upon diagnosis, in contrast to other parts of the world, suggesting that a large unmet need may be education to increase awareness and upregulate screening. There are several treatment options, however, for hormone-sensitive metastatic disease including abiraterone, enzalutamide and apalutamide. Additionally, triplet therapy combining chemotherapy, abiraterone and darolutamide has proven successful. This interview took place at the European Society for Medical Oncology (ESMO) Asia 2023 Congress in Singapore.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.